The therapeutic effectiveness of (177)Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest

Some patients with B-cell non-Hodkin lymphoma Lymphoma (NHL) become refractory to rituximab (anti-CD20 antibody) therapy associated with chemotherapy. Here, the effect of the anti-CD37 antibody-radionuclide conjugate lutetium-177 ((177)Lu)-lilotomab (Betalutin(®)) was investigated in preclinical mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Pichard, Alexandre, Marcatili, Sara, Karam, Jihad, Constanzo, Julie, Ladjohounlou, Riad, Courteau, Alan, Jarlier, Marta, Bonnefoy, Nathalie, Patzke, Sebastian, Stenberg, Vilde, Coopman, Peter, Cartron, Guillaume, Navarro-Teulon, Isabelle, Repetto-Llamazares, Ada, Heyerdahl, Helen, Dahle, Jostein, Bardiès, Manuel, Pouget, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192854/
https://www.ncbi.nlm.nih.gov/pubmed/31836849
http://dx.doi.org/10.1038/s41375-019-0677-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192854/
https://www.ncbi.nlm.nih.gov/pubmed/31836849
http://dx.doi.org/10.1038/s41375-019-0677-4

Ejemplares similares